GRCL (Gracell Biotechnologies) Market Value to Book Value Ratio

Official company branding of Gracell Biotechnologies (GRCL)

The integration of Chinese developments into a Western structure has neutralized geopolitical risks for Gracell Biotechnologies (GRCL). Strategic alliances and substantial investments ensure capital stability during clinical trials. The shift in the company's P/BV ratio reflects business maturity, where 4.39 is the current level of the metric. The acquisition by AstraZeneca and the launch of the FasTCAR platform are accelerating the global market rollout of leukemia therapy.

Gracell (GRCL): Capitalization to Book Value Ratio from 07/04/2022 to 03/03/2024

Financial and market metric breakdowns for Gracell Bio (GRCL)

- price and consensus price forecast:
Price Chart Gracell Biotechnologies|GRCL - Price Target Chart
- market capitalization data:
Market Value Gracell Biotechnologies Ltd|GRCL - Total Enterprise Value
- book capitalization data:
Net Assets per Single Share Gracell Biotechnologies|GRCL - Accounting Capitalization|Market Capitalization to Book Value Ratio gracellbio.com|GRCL - Cumulative Company Assets
- debt and liquidity data:
Debt to Equity Gracell Biotechnologies|GRCL - Long-Term Liabilities to Capital|Short-Term Debt to Equity Gracell Biotechnologies Ltd|GRCL - Company Debts|Debt to Book Capitalization Ratio Gracell Biotechnologies Ltd
Fundamental valuation:Gracell Biotechnologies
Brand item of Gracell Biotechnologies Ltd

This metric compares the market value of Gracell Biotechnologies (GRCL) to its net assets. The formula measures the premium investors are willing to pay for equity relative to its book value. By analyzing this price-to-book multiplier chart, one can assess the extent of inflated market expectations. High values reflect confidence in the success of CAR-T therapy; however, a technological breakthrough by competitors in cell engineering could instantaneously erode this premium.

Competitor analysis

Legend Biotech (LEGN) - Market Value to Book Value Ratio|SANA (sana.com) - Market Value to Book Value Ratio|Market Value to Book Value Ratio AUTL (Autolus Therapeutics plc)|Market-to-Book Ratio ALLO|Market Value to Book Value Ratio Cartesian Therapeutics Inc RNAC|Capitalization to Book Value Ratio cellectis.com (CLLS)|Caribou Biosciences - Market Capitalization to Book Value Ratio|instilbio.com - Market Cap to Net Assets Ratio|GNTA (Genenta) - Market Value to Book Value Ratio|IPSC: Market-to-Book Ratio|jaspertherapeutics.com (JSPR) - Market Value to Book Value Ratio|SNTI (Senti Biosciences) - Market Value to Book Value Ratio|Market Value to Book Value Ratio ADAP (Adaptimmune Therapeutics plc)|Market-to-Book Ratio CERo Therapeutics Holdings Inc.|TCRT: Market Capitalization to Book Value Ratio|Market Value to Equity Ratio achillestx.com ACHL|CRGX: Market Cap to Net Assets Ratio|PSTX - Market-to-Book Ratio|Market Cap to Net Assets Ratio 2seventy bio, Inc. (TSVT)